Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov 22;15(11):e250601.
doi: 10.1136/bcr-2022-250601.

Kikuchi-Fujimoto disease following SARS-CoV-2 vaccination

Affiliations
Case Reports

Kikuchi-Fujimoto disease following SARS-CoV-2 vaccination

Kohsuke Ikeda et al. BMJ Case Rep. .

Abstract

A previously healthy Japanese woman in her 20s was admitted to our hospital with a 2-week history of fever (39.0°C) and a 1-week history of painful cervical lymphadenopathy. The day before fever onset, she had received her first Pfizer-BioNTech SARS-CoV-2 vaccine in her left arm. She had previously been treated with empirical antibiotics with no improvement. Physical examination revealed painful lymphadenopathy in both posterior cervical regions. CT showed symmetrical lymphadenopathies in the neck, supraclavicular, axillary and inguinal regions as well as hepatosplenomegaly. We suspected lymphoma and performed a lymph node biopsy in the right inguinal region, which revealed necrotising histiocytic lymphadenitis. The patient was, therefore, diagnosed with Kikuchi-Fujimoto disease (KFD). She improved after the corticosteroid therapy. This report highlights the importance of including KFD as a differential diagnosis of lymphadenopathy after SARS-CoV-2 vaccination. Additionally, lymph node biopsy is helpful for diagnosing KFD because it rules out other entities.

Keywords: COVID-19; Medical education; Vaccination/immunisation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Timeline of clinical progress. CRP, C reactive protein; ESR, erythrocyte sedimentation rate; LO, lactate dehydrogenase; PSL, prednisolone; WBC, white blood cells.
Figure 2
Figure 2
CT findings. CT scans showed lymphadenopathy in the (A) bilateral cervical regions, (B) left supraclavicular fossa, (C, D) bilateral axillae and (E) right inguinal region (white arrow) as well as (F) hepatosplenomegaly.
Figure 3
Figure 3
Histopathologic findings. The patient underwent an excisional right inguinal lymph node biopsy. (A) Large and small foci and fusion of histiocytes and lymphocytes were seen from the paracortex to the cortex of the lymph node. Apoptosis and nuclear debris were observed in the central part of the lesion, and abundant histiocytes were phagocytosing this debris. No neutrophils or eosinophils were seen. Immunostaining showed an increase in (B) CD3+, (C) CD4+, and (D) CD8+ T cells and (E) CD68+ histiocytes. (F) No CD20+ B cells were seen. Histopathological features of the lymph nodes of patients with Kikuchi-Fujimoto disease include numerous phagocytic histiocytes, lymphocytes, marked nuclear debris and apoptosis. Neutrophils and eosinophils are generally absent. Immunohistological findings predominately comprise CD68+ histiocytes, CD4+ T cells and CD8+ T cells, with few B cells. These findings confirmed histiocytic necrotising lymphadenitis in the present case.

References

    1. Perry AM, Choi SM. Kikuchi-Fujimoto disease: a review. Arch Pathol Lab Med 2018;142:1341–6. 10.5858/arpa.2018-0219-RA - DOI - PubMed
    1. Pepe F, Disma S, Teodoro C, et al. . Kikuchi-Fujimoto disease: a clinicopathologic update. Pathologica 2016;108:120–9. - PubMed
    1. Mansoor CA, Shemin Z. Kikuchi-Fujimoto disease with multiple extra-nodal features - A clinical mimic. Reumatismo 2019;71:105–7. 10.4081/reumatismo.2019.1130 - DOI - PubMed
    1. Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs 2021;81:495–501. 10.1007/s40265-021-01480-7 - DOI - PMC - PubMed
    1. Meo SA, Bukhari IA, Akram J, et al. . COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci 2021;25:1663–9. 10.26355/eurrev_202102_24877 - DOI - PubMed

Publication types

MeSH terms

Substances